Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PDC-1421 is an oral botanical formulation derived from the root of Polygala tenuifolia (Radix polygalae), developed as a potential treatment for major depressive disorder (MDD) and attention-deficit hyperactivity disorder (ADHD). The active pharmaceutical ingredient, also known as Radix polygalae extract, acts primarily as a norepinephrine transporter (NET) inhibitor, thereby modulating norepinephrine reuptake in the brain. This mechanism is associated with antidepressant and sedative effects. Clinical studies have shown that PDC-1421 can significantly reduce depressive symptoms and improve focus in ADHD patients, with a favorable safety profile compared to traditional antidepressants[1][2][3][5][6]. The drug is being developed by BioLite (a subsidiary of ABVC BioPharma), with involvement from several academic institutions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PDC-1421.